P
Phioanh L. Nghiemphu
Researcher at University of California, Los Angeles
Publications - 172
Citations - 9524
Phioanh L. Nghiemphu is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Glioma & Medicine. The author has an hindex of 48, co-authored 146 publications receiving 8085 citations. Previous affiliations of Phioanh L. Nghiemphu include University of California & Emory University.
Papers
More filters
Journal ArticleDOI
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Timothy F. Cloughesy,Aaron Mochizuki,Joey Orpilla,Willy Hugo,Alexander Lee,Tom B. Davidson,Anthony C. Wang,Benjamin M. Ellingson,Julie A. Rytlewski,Catherine Sanders,Eric S. Kawaguchi,Lin Du,Gang Li,William H. Yong,Sarah C. Gaffey,Adam L. Cohen,Ingo K. Mellinghoff,Eudocia Q. Lee,David A. Reardon,Barbara O’Brien,Nicholas Butowski,Phioanh L. Nghiemphu,Jennifer Clarke,Isabel Arrillaga-Romany,Howard Colman,Thomas Kaley,John de Groot,Linda M. Liau,Patrick Y. Wen,Robert M. Prins +29 more
TL;DR: It is suggested that the neoadjuvant administration of PD-1 blockade enhances both the local and systemic antitumor immune response and may represent a more efficacious approach to the treatment of this uniformly lethal brain tumor.
Journal ArticleDOI
Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma
Timothy F. Cloughesy,Koji Yoshimoto,Phioanh L. Nghiemphu,Kevin M. Brown,Julie Dang,Shaojun Zhu,Teli Hsueh,Yinan Chen,Wei-wei Wang,David Youngkin,Linda M. Liau,Neil A. Martin,Don Becker,Marvin Bergsneider,Albert Lai,Richard M. Green,Tom Oglesby,Michael Koleto,Jeff Trent,Steve Horvath,Paul S. Mischel,Ingo K. Mellinghoff,Charles L. Sawyers +22 more
TL;DR: Rapamycin has anticancer activity in PTEN-deficient glioblastoma and warrants further clinical study alone or in combination with PI3K pathway inhibitors.
Journal ArticleDOI
Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
Albert Lai,Anh Tran,Phioanh L. Nghiemphu,Whitney B. Pope,Orestes E. Solis,Michael T. Selch,Emese Filka,William H. Yong,Paul S. Mischel,Linda M. Liau,Surasak Phuphanich,Keith L. Black,Scott Peak,Richard M. Green,Cynthia E. Spier,Tatjana Kolevska,Jonathan Polikoff,Louis Fehrenbacher,Robert Elashoff,Timothy F. Cloughesy +19 more
TL;DR: Comparative subset analysis showed that poor prognosis patients (recursive partitioning analysis class V/VI) may derive an early benefit from the use of first-line BV and TMZ during and after RT showed improved PFS without improved OS compared to the University of California, Los Angeles/KPLA control group.
Journal ArticleDOI
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
Albert Lai,Samir Kharbanda,Whitney B. Pope,Anh Tran,Orestes E. Solis,Franklin Peale,William F. Forrest,Kanan Pujara,Jose Carrillo,Ajay Pandita,Benjamin M. Ellingson,Chauncey W. Bowers,Robert Soriano,Nils Ole Schmidt,Sankar Mohan,William H. Yong,Somasekar Seshagiri,Zora Modrusan,Zhaoshi Jiang,Kenneth Aldape,Paul S. Mischel,Linda M. Liau,Cameron Escovedo,Weidong Chen,Phioanh L. Nghiemphu,C. David James,Michael D. Prados,Manfred Westphal,Katrin Lamszus,Timothy F. Cloughesy,Heidi S. Phillips,Heidi S. Phillips +31 more
TL;DR: Although histologically similar, GBMs arising with and without IDH1(R132MUT) appear to represent distinct disease entities that arise from separate cell types of origin as the result of largely nonoverlapping sets of molecular events.
Journal ArticleDOI
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
Jeffrey C. Lee,Jeffrey C. Lee,Igor Vivanco,Rameen Beroukhim,Rameen Beroukhim,Julie H. Y Huang,Whei Feng,Whei Feng,Ralph M. Debiasi,Ralph M. Debiasi,Koji Yoshimoto,J. King,Phioanh L. Nghiemphu,Yuki Yuza,Qing-Qing Xu,Heidi Greulich,Heidi Greulich,Roman K. Thomas,Roman K. Thomas,J. Guillermo Paez,J. Guillermo Paez,Timothy C. Peck,Timothy C. Peck,David Linhart,David Linhart,Karen A. Glatt,Gad Getz,Robert C. Onofrio,Liuda Ziaugra,Ross L. Levine,Stacey Gabriel,Tomohiro Kawaguchi,Keith O'Neill,Haumith Khan,Linda M. Liau,Stanley F. Nelson,P. Nagesh Rao,Paul S. Mischel,Russell O. Pieper,Timothy F. Cloughesy,Daniel J. Leahy,William R. Sellers,William R. Sellers,Charles L. Sawyers,Matthew Meyerson,Matthew Meyerson,Ingo K. Mellinghoff +46 more
TL;DR: The results suggest extracellular missense mutations as a novel mechanism for oncogenic EGFR activation and may help identify patients who can benefit from EGFR kinase inhibitors for treatment of glioblastoma.